News

Reverdia and Helm join forces
Enlarge image

BusinessNetherlandsFranceGermany

Reverdia and Helm join forces

18.10.2012 - Reverdia and Helm have partnered to market the bioplastics compound succinic acid on industrial scale.

Reverdia, the joint venture from Dutch DSM and French Roquette, has joined forces with Hamburg-based Helm AG for production and marketing in the highly competitive European market for bio-based succinic acid. The chemical building block for bioplastics, organic solvents and elastic fibres, is predicted to reach sales of 4-7bn annually in the mid-term.

„Reverdia’s Biosuccinium does not only offer an alternative to petrochemical succinic acid, but also for other fossil-based acids like adipic acid, so the market potential is huge”, stressed Christina Wienholz, Senior Executive Manager at Helm, who will take the part of marketing. “Our partnership with Helm will deliver expanded market development capacity for Reverdia in Europe“, said Reverdia chief Jo Kockelkoren, whose company has set up a plant-derived sugar fermentation process in yeast. His company aims at becoming the first company in the world to produce succinic acid on commercially large scale. Reverdia plans to complete a production plant with an annual capacity of 10,000 metric tons in Cassano Spinola, Italy, at the end of this year.

The move came just a week after German chemical major BASF and its Dutch partner Purac N.V. announced a joint-venture named Succinity to produce and market succinic acid. The companies want to start production after reconstruction of a 10,000 ton plant near Barcelona is finished in late 2013. US firm Myriant Inc. has also announced completion of construction of a 13,000 ton bio-succinic acid production plant in Quincy, Massachusetts, for the end of 2012. Bioamber Inc. is already marketing the bio-based compound since 2011, which is produced from E. coli in its Pomacle plant (France) that has an annual capacity of 2,000 metric tons. Succinity, however, may have a competitive edge because its process can also use glycerol, a byproduct of biodiesel production, as a feedstock.

According to the companies, biosuccinic acid could be used to produce coolants, surfactants, adhesives, corrosion inhibitors, lubricants, photo development fluids, herbicides, soldering pastes, runway deicers, polyurethanes, coating resins, phthalate-free plasticizers, polybutylene succinate (PBS) and many others.

© eurobiotechnews.eu/tg

RegulationUKEU

29.07.2014 The first vaccine for malaria may be within reach: The European Medicines Agency has accepted Glaxosmithkline’s malaria vaccine candidate RTS,S for regulatory review.

FundingEU

25.07.2014 The European Commission aims to support innovation in Europe and announced a "Fast Track to Innovation" pilot as well as five innovation prices under Horizon 2020.

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR229.4%
  • ADDEX (CH)4.01 CHF67.1%
  • 4SC (D)1.42 EUR46.4%

FLOP

  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-24.0%
  • VITA 34 (D)4.21 EUR-19.8%

TOP

  • SANTHERA (CH)65.50 CHF3095.1%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR302.9%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.28 CHF-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.6%

No liability assumed, Date: 29.07.2014